Glenmede Investment Management’s Nektar Therapeutics NKTR Stock Holding History

Glenmede Investment Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$523K	Buy	+9,200	New	+$305K	﹤0.01%	913

Other funds holding NKTR

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Glenmede Investment Management's NKTR Position: Q3 2025 in Review

Glenmede Investment Management opened a new position in Nektar Therapeutics (NKTR) in Q3 2025: 9,200 shares worth $523K. The stake represents ﹤0.01% of the portfolio and ranks #913 among its holdings.

154 funds tracked by Wall St. Rank hold NKTR as of Q3 2025.

Glenmede Investment Management held 9,200 shares of Nektar Therapeutics worth $523K as of Q3 2025.
Nektar Therapeutics was a new Glenmede Investment Management position in Q3 2025.
Nektar Therapeutics made up ﹤0.01% of Glenmede Investment Management's portfolio in Q3 2025, its #913 holding.
154 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.